NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$63.98
-2.55 (-3.83%)
Close of Nov 06, 2026 · end-of-day data
INSP 8-K filings in 2025
Every material Form 8-K Inspire Medical Systems filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Inspire Medical Systems reported third-quarter 2025 revenue of $224.5 million, up 10%, but net income fell to $9.9 million from $18.5 million, and diluted EPS was $0.34 versus $0.60 a year earlier. The company raised its full-year 2025 diluted EPS guidance to $0.90 to $1.00 from $0.40 to $0.50 while maintaining full-year revenue guidance of $900 million to $910 million.
Q3 revenue was $224.5 million, up 10% from $203.2 million; U.S. revenue was $214.4 million, up 9%.
Net income was $9.9 million versus $18.5 million, and diluted EPS was $0.34 versus $0.60 a year earlier.
Full-year 2025 diluted EPS guidance raised to $0.90 to $1.00 from $0.40 to $0.50; revenue guidance maintained at $900 million to $910 million.
Operating expenses rose 17% to $183.1 million, and cash, cash equivalents and investments were $410.9 million at September 30, 2025.
Inspire Medical Systems said Chief Financial Officer Richard Buchholz will step down to pursue other professional opportunities, effective December 31, 2025 or the day before a permanent successor starts, whichever is earlier. The company said his decision was not due to any disagreement over operations, policies, or accounting and financial reporting, and it has begun a search for a new CFO. The company also reaffirmed its full-year 2025 guidance.
Buchholz will remain principal financial and accounting officer until his resignation takes effect, then serve in a financial advisory role through February 28, 2026
Transition terms include a cash payment equal to nine months of his 2025 base salary and up to nine months of COBRA coverage
Full-year 2025 guidance reaffirmed: revenue of $900 million to $910 million, gross margin of 84% to 86%, and diluted net income per share of $0.40 to $0.50
Inspire Medical Systems reported second-quarter 2025 revenue of $217.1 million, up 11%, but posted a GAAP net loss of $3.6 million and cut its full-year 2025 revenue and diluted EPS guidance. Management said the U.S. launch of Inspire V is progressing slower than expected and the timeline for the full transition has been pushed out, which will affect results for the year. The filing also discloses that Executive Vice President Randall A. Ban will retire on January 30, 2026.
Q2 2025 revenue was $217.1 million, up from $195.9 million; GAAP net loss was $3.6 million, or $0.12 per share, versus net income of $9.8 million a year earlier.
2025 revenue guidance lowered to $900 million to $910 million from $940 million to $955 million; diluted EPS guidance lowered to $0.40 to $0.50 from $2.20 to $2.30.
Gross margin was 84.0% versus 84.8% a year earlier, including a $2.1 million charge for excess Inspire IV components inventory.
EVP Randall A. Ban notified the company on July 31, 2025 of his intent to retire on January 30, 2026.
Inspire Medical Systems reported first quarter 2025 revenue of $201.3 million, up 23% from a year earlier, and diluted earnings of $0.10 per share compared with a loss of $0.34 per share in the prior-year quarter. The company maintained its full year 2025 revenue guidance of $940 million to $955 million and raised its diluted EPS guidance to $2.20 to $2.30 from $2.10 to $2.20.
Q1 2025 revenue was $201.3 million, up 23% from $164.0 million; U.S. revenue rose 24% to $193.6 million, while revenue outside the U.S. fell 6% to $7.7 million
Q1 2025 net income was $3.0 million, compared with a net loss of $10.0 million a year earlier; operating loss narrowed to $1.5 million from $15.2 million
Full year 2025 revenue guidance of $940 million to $955 million was maintained; diluted EPS guidance was raised to $2.20 to $2.30
Cash, cash equivalents and investments were $414.0 million at March 31, 2025, versus $516.5 million at December 31, 2024
Inspire Medical Systems reported fourth-quarter 2024 revenue of $239.7 million, up 25% from a year earlier, and diluted earnings per share of $1.15 versus $0.49. It also reaffirmed 2025 revenue guidance of $940 million to $955 million and introduced 2025 diluted EPS guidance of $2.10 to $2.20, which gives shareholders a profit target for the year.
Q4 2024 net income was $35.2 million, with diluted EPS of $1.15 versus $0.49 a year earlier
Full-year 2024 revenue was $802.8 million, up 28%, with net income of $53.5 million and diluted EPS of $1.75
2025 revenue guidance of $940 million to $955 million was reaffirmed; diluted EPS guidance of $2.10 to $2.20 was introduced
Q4 2024 gross margin was 85.0%, compared with 85.4% a year earlier
Inspire Medical Systems reported preliminary, unaudited fourth-quarter 2024 revenue of $239.5 million to $239.7 million, about 25% higher than a year earlier, and full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%. The company also gave initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase, and announced leadership changes, including a new Chief Manufacturing and Quality Officer. The figures are estimates that may change before the full 2024 results are reported in the Form 10-K.
Preliminary Q4 2024 revenue of $239.5 million to $239.7 million, up about 25% year over year
Preliminary full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%
Initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase
Jason Kelly named Chief Manufacturing and Quality Officer effective January 20, 2025; Chief Medical Officer Charisse Sparks left the company at the beginning of 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Inspire Medical Systems filing is on SEC EDGAR ↗. 8-K briefs of other companies →